Background. The instantaneous inhibitory potential (IIP), a measure of antiviral activity that incorporates the slope of the dose-response curve, has been proposed as a better predictor of clinical efficacy than the inhibitory quotient (IQ). However, there are no quantitative analyses supporting this hypothesis.
differences in percentage of subjects with plasma human immunodeficiency virus type 1 (HIV-1) RNA levels !50 copies/mL at week 48 was determined for antiretroviral drugs compared in 17 randomized clinical trials. The , , , were correlated with differences in percentage of subjects with HIV-1 RNA levels !50 copies/mL in each trial. , , , and were calculated using published median effect model slope values and log (IQ ) log (IQ ) IIP  IIP   10  24  10  12  24  12 values; values from linear regression and Spearman correlation coefficients were calculated for each analysis; and correlation coefficients were compared between and IIP. log (IQ) 10 
Results.
values were greatest for the and comparisons using intention-to-treat and were 0.05 and 0.18, respectively. Differences in Spearman rank correlation coefficients between DIIP 12 and IIP at each drug concentration were not significantly different, with the exception of log (IQ) D log (IQ ) 10 10 max and ; the correlation was significantly stronger than the correlation. DIIP D log (IQ ) DIIP max 10 max max
Conclusions. IIP was not substantially better than in describing the modest relationship between log (IQ) 10 antiviral activity, pharmacokinetics, and virologic outcomes for antiretroviral drugs.
Reliable laboratory and mathematical models to predict the antiretroviral activity of candidate drugs could aid the selection of novel agents for clinical development. Widely used measures to quantify antiviral activity include the amount of drug required to inhibit 50% of viral activity in vitro ( ) and the inhibitory quotient IC 50 (IQ), which is the trough drug concentration divided by the . The IQ shows a modest correlation with IC 50 clinical outcome [1, 2] , but outcomes can vary in relation to relatively minor changes in maximum inhibition that are not reflected in the IQ. Moreover, the shape of the dose-response curve can vary substantially between drugs with similar values because of dif-IC 50 ferences in slope. There has been interest in designing and implementing new laboratory measures that overcome existing limitations. A recent study described an index for comparing antiviral activity of different drugs using classic dose-response relationships that incorporate the slope of the inhibition curve, or Hill coefficient, for each drug [3] . The Hill coefficient was first used to describe cooperative binding in hemoglobin [4] and has a role in modeling synergy between different drugs [3, 5, 6] . This index, termed the instantaneous inhibitory potential (IIP), is defined by the following equation: where represents the fraction of viruses in a single-round f u infectivity assay unaffected by drug, represents antiviral con-C t centrations at a specific time (t), and m represents the slope from the median effect model of mass action.
The IIP has been proposed as a better predictor of antiviral activity in vivo than the IQ because it takes into account the intrinsic antiviral potency of a drug and potentially the cooperativity of drugs used in combination [3, 7, 8] . It was also proposed that the slope parameter of the IIP is class specific and defines intrinsic limitations on antiviral activity in some classes [3] . However, the IIP has not been compared rigorously to traditional pharmacologic measures, such as the IQ, and it is unclear whether the IIP is a better indicator of virologic response. Correlating in vitro antiviral activity with virologic outcomes has been challenging, given the diverse ways in which virologic response data are analyzed and the complexities of extrapolating antiviral activity to predict outcome measures. To test the hypothesis that the IIP provides a better measure of clinical outcome than previous pharmacodynamic metrics, we compared the correlation between differences in the IIP or the IQ and differences in virologic response between pairs of antiretroviral agents, using data from 17 randomized clinical trials of antiretroviral drugs. Table 1 lists the clinical trials included in the analysis. Published phase 2b or phase 3 randomized trials were included for analysis if they reported the proportion of subjects with plasma human immunodeficiency virus type 1 (HIV-1) RNA levels !50 copies/mL at 48 weeks or 1 year (with the exception of AIDS Clinical Trial Group [ACTG] A5142, which reported HIV-1 RNA levels at 96 weeks) and if the pharmacokinetic data required to calculate the IQ and IIP were available [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Our analysis incorporated data from 11 clinical trials originally addressed by Shen et al [3] , as well as data from 6 additional trials that compared antiretroviral drugs from various classes [9] [10] [11] [12] [13] [14] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] .
METHODS

Data source.
Results of intention-to-treat (ITT) analyses of virologic outcomes were used in the primary analysis; if several analyses were reported, data were used from the analysis in which switch or discontinuation of treatment equaled failure, whenever possible. Data from ITT analyses were reported most consistently and were similar to those presented in the original description of the IIP [3] .
Study design. The difference in the percentage of study subjects achieving virologic suppression was plotted against the difference in values ( ) or the difference in log (IQ) D log (IQ) 10 10 IIP values (DIIP) for the drugs being compared in a particular trial. Separate analyses were performed using minimum and maximum steady- the basis of published virologic and pharmacokinetic data or data from the US Food and Drug Administration-approved prescribing information (package insert). Drug concentrations 12 and 24 h after were calculated using the classic decay C max equation [3] :
where , and t is the time after .
Statistical analyses. Linear regression curve fitting was performed using Graphpad, version 5 (Graphpad Software). Slopes, 95% confidence intervals (CIs) for the slope, values, 2 r and 95% CIs for the regression line from best-fit values were calculated. Spearman (rank-based) correlation coefficients and P values were also calculated using Graphpad, version 5. Dependent intercorrelation comparisons using Student's t tests were performed using SISA [28] . The nominal level of significance was defined as . P p .05 slopes for these correlations had overlapping 95% CIs (Figure 1) .
RESULTS
Results of Spearman (rank-based) correlation analyses were consistent with those of the linear regression models. All the comparisons revealed modest, statistically significant correlations between differences in virologic outcome and D log (IQ) 10 
or
, with the exception of . The correlation coeffi-DIIP DIIP max cients are listed in Table 2 
DISCUSSION
In this study, we explored the correlation between the IIP of antiretroviral drugs and their virologic efficacy and sought to determine whether differences in the IIP might predict the outcome of randomized clinical trials comparing 2 antiretroviral regimens better than would differences in the IQ. A previous study suggested that, by incorporating the slope, or steepness, of the drug inhibition curve, the IIP represented a more accurate pharmacodynamic measure of in vivo antiviral activity than did traditional parameters and may play a major role in determining virologic outcomes [3] . This new measure has generated a great deal of interest since its introduction, especially because it has been purported to predict differences in potency of different antiviral classes; the IIP has also been proposed as a tool for selecting new drugs for clinical development [3, 7, 8] . Our analysis of data from 17 randomized clinical trials of antiretroviral drugs (ITT analysis) found that differences in the IIP between drugs did show a modest correlation with differences in virologic outcome but that these correlations were not significantly stronger than were the correlations obtained using the IQ. The strongest correlations between difference in pharmacokinetic variables and difference in percentage with virologic suppression from linear regression modeling were for , , and , whereas D log (IQ ) D log (IQ ) D log (IQ ) 10 12 10 24 10 min the strongest Spearman correlations were for , D log (IQ ) 10 24 , and . Differences between analyses were DIIP D log (IQ ) 24 10 12 ; these results are not surprising, given the relatively small DIIP 24 sample size used in the correlation analysis.
Figure 1. Scatter plots of difference in (D) percentage of patients in intention-to-treat analysis who demonstrated viral load (VL)
Despite positive correlations between the difference in virologic outcome and or DIIP overall, the correlation D log (IQ) 10 in many individual studies fell well outside the 95% confidence limits of the linear regression plots. In some cases, small differences in treatment outcome between arms were observed despite substantial differences in the IIP or IQ between the comparator drugs; conversely, in other studies, significant differences in outcome were observed despite modest differences in the IIP or IQ. Although this finding may reflect the uncertainty in the estimated difference in both virologic and pharmacokinetic effect sizes, it suggests that variables other than intrinsic drug activity and pharmacokinetics, such as adherence, concentrations 24 h after . D, Difference in values for antivirals compared. C max tolerability, dosing convenience, and emergence of resistance, are important contributors to the overall clinical effectiveness of a drug or regimen. The predictive capacity of both the IIP and the IQ are therefore inherently limited by the complex factors encountered during the extrapolation of in vitro measures to virologic outcome in clinical trials.
While it is tempting to conclude that molecules with a steeper dose-response curve make better drugs, clinical experience suggests that other properties, such as the pharmacokinetic profile, tolerability and dosing convenience, may be more important determinants of drug efficacy. For example, the slope of the inhibition curve for indinavir is substantially greater than that for efavirenz (Figure 1d and Supplementary Table 1 in the article by Shen et al [3] ), but efavirenz is more effective than indinavir because of its longer half-life and better tolerability [14] . Likewise, lopinavir and nelfinavir have similar slope values [3] , but comparative trials show that lopinavir/ritonavir is superior to nelfinavir [20] . The generally similar correlation between the IIP and IQ with virologic outcome in the trials we studied suggests that drug susceptibility (as measured by ) IC 50 and pharmacokinetic parameters (as measured by , , C C min max , etc), which are common to the IIP and IQ, dominate the t 1/2 slope in determining drug efficacy.
The 48-week end point (ITT analysis; switch or noncompletion of treatment equals failure, when available) was chosen for primary analysis for 3 major reasons: (1) similar data were used in the original description of the IIP [3] , (2) it was the primary end point of most of the studies incorporated in our analysis, and (3) there are limitations to publicly available astreated data or data from earlier time points. Factors such as drug toxicity, tolerability, baseline drug resistance, variations in background antiviral therapies, and loss to follow-up no doubt contributed to overall regimen efficacy but are not captured by either the IIP or the IQ. However, the aim of this exploratory analysis was to provide a quantitative estimate of the association between pharmacodynamic properties of different drugs and virologic outcomes and was consistent with the approach taken in the original report on the IIP. However, that report did not formally test the relative strength of association of the IIP and other traditional pharmacodynamic metrics with virologic outcomes in clinical trials [3] , making it difficult to infer superiority of one laboratory measure over another.
Although using as-treated or per-protocol data may partially control for potentially confounding factors, such as drug toxicity, tolerability, and medication cross-over, there are limitations with this potential approach. As-treated results may involve an end point in which subjects are censored at treatment discontinuation, which would be informative in our comparison between the IIP and IQ. However, many trials do not define early discontinuation of patients, and the as-treated results represent a cross-sectional analysis of patients still randomized at week 48. This analysis discounts early treatment discontinuation for inadequate virologic outcome and leads to informative censoring. Although a method for carrying forward the last HIV-1 RNA level to subsequent time points for a patient who discontinues treatment early during a study protocol may overcome some of the informative censoring, this type of analysis is not possible without access to raw data for all trials. Furthermore, this manipulation does not necessarily overcome the problem of bias created by early discontinuation before a study subject has had a chance to have a response to medication.
A method of quantifying treatment differences for both a major clinical outcome and a surrogate marker and for measuring the strength of association between these values has been described [29] . This approach requires that measurements of the surrogate marker and the clinical end point come from one group of individuals or from a single study or requires an allowance of precision to be assessed for treatment differences across studies [29] . We could not apply this approach to our analysis, because it requires access to raw data from each of the respective clinical trials. Moreover, in the current analysis, the treatment effect was estimated across trials with different sample sizes and different degrees of precision, which were not taken into consideration. Furthermore, few of these studies included measurement of both pharmacokinetic parameters and longer-term clinical outcomes, which would be necessary for a more complete analysis. However, all the virologic studies included in our analysis were based on robust clinical trials with relatively large study populations. Spearman rank correlations were chosen to reduce emphasis on individual trial size and the strength of each correlation data point, as well as to compensate for potential lack of linearity between variables.
Despite these limitations, this study provides an in-depth, quantitative comparison of the relationship between the , IIP, and virologic outcome. Our analysis shows D log (IQ) 10 that the insights that the IIP provides into the kinetics of drug activity at the cellular and biochemical level do not translate into substantially better predictions of efficacy from primary outcomes of major clinical trials than traditional measures such as the IQ. The slope of the dose-response curve used in calculation of the IIP may be an important factor influencing in vivo antiviral activity, but better models are needed for predicting the relative efficacy of antiretroviral regimens that incorporate these additional pharmacokinetic and cooperative drug parameters.
